ProKidney Corp. filed a Form S-3 registration statement with the SEC on October 29, 2026, seeking to register up to $650,000,000 in securities, including a $200,000,000 at-the-market equity program with Jefferies LLC.

Key Highlights

  • Total shelf size: The filing registers up to $650,000,000 in the aggregate of Class A common stock, preferred stock, debt securities, warrants, rights, and units.
  • ATM program: A separate sales agreement prospectus covers up to $200,000,000 of Class A common stock to be sold from time to time under an Open Market Sale Agreement with Jefferies LLC.
  • ATM inclusion: According to the filing, the $200,000,000 ATM amount is included within, not in addition to, the $650,000,000 aggregate shelf amount.
  • Stock price at filing: The last reported sale price of Class A common stock on October 28, 2026 was $1.52 per share, as disclosed in the prospectus.
  • Company classifications: ProKidney is classified as a non-accelerated filer, smaller reporting company, and emerging growth company under applicable SEC rules.
  • Listing: Shares of Class A common stock are listed on the Nasdaq Capital Market under the symbol "PROK."

ProKidney's Dual-Prospectus Shelf Structure and ATM Agreement Details

ProKidney Corp. (NASDAQ:PROK) filed a Form S-3 shelf registration statement on October 29, 2026, covering two prospectuses within a single registration. The base prospectus covers the potential offering, issuance, and sale of up to $650,000,000 in securities, which may include any combination of Class A common stock, preferred stock, debt securities, warrants, rights, and units, either individually or in units. The filing states that securities may also be issued upon conversion of or exchange for other registered securities, or upon the exercise of warrants or rights.

A separate sales agreement prospectus within the same registration covers up to $200,000,000 of Class A common stock that may be offered under an Open Market Sale Agreement with Jefferies LLC. The filing clarifies that this $200,000,000 is included within the overall $650,000,000 shelf limit. If the sales agreement with Jefferies is terminated and no shares have been sold under it, the full $650,000,000 remains available under the base prospectus. Specific terms of any offering under the base prospectus will be set out in a prospectus supplement at the time of each offering.

The company's principal executive offices are located at 2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, NC 27103, and Bruce Culleton, M.D. is identified as Chief Executive Officer and agent for service. The registration statement has not yet become effective, and the filing includes standard language that securities may not be sold until the registration statement is declared effective by the SEC. The filing notes that investing in the company's securities "involves a high degree of risk," directing prospective investors to the Risk Factors section beginning on page 6 of the prospectus.

What Was Disclosed

ProKidney Corp. filed a Form S-3 shelf registration on October 29, 2026, registering up to $650,000,000 in mixed securities and establishing a $200,000,000 at-the-market equity program with Jefferies LLC, with the ATM amount counted within the larger shelf total.